Want to see JP:7777 full AI Analyst Report?
Top Page
3-D Matrix
(7777)
Select Model
Select Model
Rating:65Neutral
Price Target:
¥482.00
▲(33.52% Upside)
Action:Reiterated
Date:09/15/26
The score is driven mainly by the financial turnaround (strong revenue growth and a swing to profitability plus a healthier balance sheet), but it is held back by weak cash-flow conversion and a history of cash burn. Technicals are moderately supportive in the short term, and valuation looks reasonable with a mid-teens P/E.
Positive Factors
Rapid Revenue Scaling
Rapid and accelerating revenue growth indicates expanding commercial activity and improving market traction. If maintained, this larger revenue base can support operating leverage, strengthen the company’s competitive position, and provide greater capacity to fund product development and future expansion.
Negative Factors
Weak Cash-Flow Conversion
Small operating and free cash flows relative to reported net income weaken earnings quality and make the recent profit improvement less dependable. The company must demonstrate that accounting earnings consistently convert into cash, otherwise working-capital effects may constrain reinvestment and financial flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Rapid Revenue Scaling
Rapid and accelerating revenue growth indicates expanding commercial activity and improving market traction. If maintained, this larger revenue base can support operating leverage, strengthen the company’s competitive position, and provide greater capacity to fund product development and future expansion.
Read all positive factors
3-D Matrix (7777) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥52.47B
Dividend YieldN/A
Average Volume (3M)2.40M
Price to Earnings (P/E)14.2
Beta (1Y)1.79
Revenue Growth55.91%
EPS GrowthN/A
CountryJP
Employees129
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)30.37
Shares Outstanding127,981,480
10 Day Avg. Volume2,667,030
30 Day Avg. Volume2,401,863
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)9.04
Price to Sales (P/S)5.65
P/FCF Ratio166.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
3-D Matrix Business Overview & Revenue Model
Company Description
3-D Matrix, Ltd. specializes in pioneering self-assembling peptide technology. Its flagship product, PuraMatrix, is an innovative self-assembling peptide hydrogel with diverse applications across medical fields, including regenerative medicine, ce...
3-D Matrix Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
67
Positive
Cash Flow
41
Neutral
| Breakdown | TTM | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.92B | 10.89B | 6.93B | 4.59B | 2.31B | 1.51B |
| Gross Profit | 9.48B | 8.57B | 4.42B | 3.09B | 1.29B | 661.01M |
| EBITDA | 2.54B | 4.17B | -2.40B | 59.13M | 715.00M | 843.00M |
| Net Income | 3.69B | 4.16B | -2.50B | -255.50M | -2.45B | -1.89B |
Balance Sheet | ||||||
| Total Assets | 9.40B | 9.80B | 6.51B | 5.89B | 5.83B | 5.61B |
| Cash, Cash Equivalents and Short-Term Investments | 1.69B | 2.83B | 1.58B | 1.36B | 1.17B | 2.85B |
| Total Debt | 600.00M | 600.00M | 2.94B | 4.17B | 4.37B | 3.67B |
| Total Liabilities | 2.18B | 3.00B | 4.30B | 5.53B | 5.30B | 4.15B |
| Stockholders Equity | 7.22B | 6.80B | 2.22B | 353.31M | 524.77M | 1.46B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 368.89M | -1.73B | -1.90B | -4.60B | -2.92B |
| Operating Cash Flow | 0.00 | 396.85M | -1.71B | -1.90B | -4.59B | -2.90B |
| Investing Cash Flow | 0.00 | -42.48M | -33.30M | -29.76M | -81.50M | -79.86M |
| Financing Cash Flow | 0.00 | 786.49M | 2.01B | 2.06B | 2.96B | 4.66B |
3-D Matrix Technical Analysis
Positive
361.00
Price Trends
366.28
Positive
385.49
Positive
428.82
Negative
Market Momentum
17.46
Negative
56.81
Neutral
54.28
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7777, the sentiment is Positive. The current price of 361 is below the 20-day moving average (MA) of 388.90, below the 50-day MA of 366.28, and below the 200-day MA of 428.82, indicating a neutral trend. The MACD of 17.46 indicates Negative momentum. The RSI at 56.81 is Neutral, neither overbought nor oversold. The STOCH value of 54.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7777.
3-D Matrix Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | ¥17.25B | 11.42 | ― | 4.59% | 20.88% | 44.61% | |
65 Neutral | ¥52.47B | 14.19 | 63.82% | ― | 55.91% | ― | |
64 Neutral | ¥8.89B | 10.50 | ― | 1.94% | 9.02% | 8.88% | |
63 Neutral | ¥263.13B | 18.89 | ― | 2.05% | 1.43% | 1.86% | |
58 Neutral | ¥183.86B | 19.74 | 5.76% | 2.49% | 3.04% | -19.26% | |
57 Neutral | ¥74.21B | 21.26 | ― | 2.51% | 2.94% | 57.05% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:7777
3-D Matrix
435.00
131.00
43.09%
JP:6523
PHC Holdings Corp.
1,430.00
509.02
55.27%
JP:4549
Eiken Chemical Co., Ltd.
2,308.00
28.47
1.25%
JP:6678
Techno Medica Co., Ltd.
2,036.00
167.56
8.97%
JP:6849
Nihon Kohden Corporation
1,601.50
-35.69
-2.18%
JP:7963
Koken Ltd.
1,797.00
54.38
3.12%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.